Sign In
Buy BLUE
$4.97
+0 (+0%)
At Close: Aug 29, 2025
New York, New York--(Newsfile Corp. - March 14, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BLUE) and c
New York, New York--(Newsfile Corp. - March 12, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of bluebird bio, Inc. (NASDAQ: BLUE) between May 11
NEW YORK, March 12, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BLUE) and certain of its o
Bluebird Bio Soars After Gene Therapy Exonerated In Cancer Diagnosis
01:27pm, Wednesday, 10'th Mar 2021
Bluebird Bio said Wednesday its experimental gene therapy for blood diseases likely wasn't the culprit in a patient's cancer diagnosis, leading BLUE stock to pop in high volume. The post Bluebird Bio
Gene Editing Stocks: What BLUE, NTLA, BEAM, CRSP and EDIT Are Doing Today
01:26pm, Wednesday, 10'th Mar 2021
Gene editing stocks are on the move Wednesday with investors taking extra interest in biotech companies on news from two major players. The post Gene Editing Stocks: What BLUE, NTLA, BEAM, CRSP and ED
Bluebird's stock is up after saying illness reported in clinical trial wasn't likely caused by gene therapy
12:49pm, Wednesday, 10'th Mar 2021
Shares of Bluebird Bio Inc. gained 6.9% in trading on Wednesday after the company said it was "unlikely" that the diagnosis of acute myeloid leukemia in a patient participating in an early-stage study
DraftKings, H&R Block, Novartis and More Wednesday Afternoon Analyst Calls
12:41pm, Wednesday, 10'th Mar 2021
With the trading day more than halfway over, the broad markets were pushing higher yet again.
Why bluebird bio Stock Is Flying Higher Today
11:00am, Wednesday, 10'th Mar 2021
The biotech announced good news for its beleaguered gene therapy program.
Bluebird Bio Says Lentiviral Vector Not the Cause Of Blood Cancer Reported In Sickle Cell Study
08:29am, Wednesday, 10'th Mar 2021
Based on multiple independent analyses, Bluebird bio Inc (NASDAQ: BLUE) has announced that it is very unlikely that Suspected Unexpected Serious Adverse Reaction of acute myeloid leukemia was rel
New York, New York--(Newsfile Corp. - March 9, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of bluebird bio, Inc. (NASDAQ: BLUE) alleging
NEW YORK, March 09, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of bluebird bio, Inc. (NASDAQ: BLUE) between May 11, 2020 and
New York, New York--(Newsfile Corp. - March 9, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of
New York, New York--(Newsfile Corp. - March 8, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of bluebird bio, Inc. (NASDAQ: BLUE) alleging
INVESTOR ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action Lawsuit Against bluebird bio, Inc.
07:04pm, Monday, 08'th Mar 2021
NEW YORK--(BUSINESS WIRE)---- $BLUE--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the District of Massachusetts on behalf of
New York, New York--(Newsfile Corp. - March 8, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of bluebird bio, Inc. (NASDAQ: BLUE) between May 11,
